Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MGAM | O43451 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SI | P14410 | 3/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268433 | 0.91 | MAOB (0.49) | ALOX5MAOBP2RY14HRH3MAOA | |
| SCHEMBL6086702 | 0.75 | MGAM (0.56) | ALOX5MAOBMGAMGAASI | |
| SCHEMBL6668074 | 0.72 | MAOB (0.54) | ALOX5MAOBGSTP1P2RY14MAPT | |
| SCHEMBL25876813 | 0.71 | MAOB (0.44) | MAOB | |
| SCHEMBL6087375 | 0.71 | NPSR1 (0.58) | ALOX5MAOBMGAMGAASI | |
| SCHEMBL23297253 | 0.70 | MPO (0.50) | MAOBMGAMGAASIMGAM2 | |
| SCHEMBL7174574 | 0.69 | EBP (0.67) | MAOBGSTP1HRH3MAOABCHE | |
| SCHEMBL6722898 | 0.69 | CA1 (0.60) | MAOBGSTP1MAPTNPSR1HRH3 | |
| SCHEMBL23297257 | 0.69 | EBP (0.51) | MAOBGSTP1MAPTNPSR1HRH3 | |
| SCHEMBL4813932 | 0.69 | PDGFRB (0.52) | MAPTNPSR1MAPK1NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272471-B1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | ORGANON NV (NL) | 2007-10-03 | — | — | EP | claimed |
| EP-1272471-B1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | ORGANON NV (NL) | 2007-10-03 | — | — | EP | disclosed |
| US-6686371-B2 | HAVING AN 11H-BENZO(B)FLUORENE, AN 11H-INDENO-(1,2-B) QUINOLINE, A BENZ(A)ANTHRACENE OR ANALOGOUS SKELETON AND AN AFFINITY FOR THE ESTROGEN RECEPTOR; CONTRACEPTIVES; MENOPAUSAL COMPLAINTS, OSTEOPOROSIS; ANTITUMOR AGENTS | AKZO NOBEL N.V. (NL) | 2004-02-03 | — | — | US | disclosed |
| US-20030144313-A1 | Non-steroidal, tetracylic compounds for estrogen-related treatments | N.V. ORGANON (NL) | 2003-07-31 | — | — | US | disclosed |
| EP-1272471-A1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | Akzo Nobel N.V. (NL) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001072713-A1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | AKZO NOBEL N.V. (NL) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144313-A1 | Non-steroidal, tetracylic compounds for estrogen-related treatments | ESRRA, ESRRB, ESRRG | ALOX5 1158/4885MAOB 3356/4885MGAM 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.